Highest-materiality recent filing
Stockholders approve 400,000-share increase in 2021 Incentive Plan and amendment to ESPP
Stockholders elected John Duke and Katherine A. Eade as Class II directors for three-year terms.
Harvard Bioscience furnishes May 2026 investor presentation with no material new data
Slide presentation attached as Exhibit 99.1; only cover page and forward-looking disclaimer provided in filing.
Harvard Bioscience Q1 revenue $20.8M, gross margin 59%; reaffirms FY guidance
Revenue $20.8M (down 5% YoY from $21.8M); net loss $(3.4)M vs $(50.3)M including $48M impairment.
Harvard Bioscience posts March 2026 investor presentation; no specific new data in excerpt
Filing attaches corporate slide deck dated March 2026; only cover page and forward-looking statement provided.
Q4 revenue $23.7M (down from $24.6M YoY); gross margin 59.7% (up from 57.1%).
Harvard Bioscience amends CEO pay, appoints Frost as CFO with $375k base
CEO John Duke gets base salary $515k; $100k cash bonus tied to credit facility refinancing.
Harvard Bioscience shareholders approve 1-for-10 reverse stock split to regain Nasdaq compliance
Stockholders approved reverse stock split at March 6, 2026 special meeting; 27.0M votes for, 678K against.
Harvard Bioscience preliminary Q4 revenue $23.7M, adj EBITDA $3.8M, 27% YoY growth
Preliminary Q4 revenue $23.7M, above guidance midpoint; gross margin 60% at high end of 58-60% range.
Harvard Bioscience to close Holliston facility; expects $4M annual savings from 2028
Closes Holliston, MA plant; moves US production to Minneapolis, MN; some operations to Germany, Sweden, UK.
Harvard Bioscience reduces stockholder meeting quorum to one-third of shares
Board approved amendment reducing quorum requirement for stockholder meetings from a majority to one-third of voting shares.
Harvard Bioscience publishes investor update slide presentation
Slide deck covers business strategy and outlook; no specific financial results or guidance changes.
Enters $40M senior secured credit facility (Term A $10M, Term B $22.5M, Term C $7.5M convertible at $1.00) maturing Dec 17, 2029
Harvard Bioscience on track to refinance or repay credit agreement in Q4 2025
Company in ongoing discussions to refinance or repay its existing credit agreement dated December 22, 2020.
HBIO Q3: revenues $20.6M, net loss narrows to $1.2M; Q4 guidance $22.5-$24.5M
Q3 2025 revenues $20.6M (down 6.4% YoY); gross margin 58.4% vs 58.1%.
Harvard Bioscience gets 180-day Nasdaq bid-price extension, transfers to Capital Market
Nasdaq granted until March 30, 2026 to reach $1.00 minimum bid price for 10 consecutive days.
Harvard Bioscience appoints Stephen DeNelsky to board, effective Sept 5, 2025
Stephen DeNelsky, Managing Director at Oaktree Capital Management, appointed to Board and Nominating & Governance Committee.
Harvard Bioscience grants Interim CFO Mark Frost $100K retention bonus tied to debt refinancing
Retention bonus of $100,000 for Interim CFO Mark Frost upon successful refinancing of term loan and revolver before March 15, 2026.
Harvard Bioscience Reports Q2 2025 Revenue of $20.5M, Net Loss of $2.3M, and Credit Amendment
Q2 2025 revenue of $20.5M vs $23.1M in Q2 2024; gross margin 56.4% vs 57.2%.
Harvard Bioscience gets covenant waiver, interest rate jumps to SOFR+700bps; going concern doubt
Waived defaults for failing Q2 2025 financial covenants; no covenant test for Q3 2025.
Harvard Bioscience appoints John Duke as CEO; Q2 revenue anticipated at $20.4M
Jim Green resigns as President & CEO effective July 28, 2025; retirement not due to any disagreement.
Alan Edrick resigned from Board and Audit Committee effective June 10, 2025, leaving only two audit committee members.
Harvard Bioscience out of compliance with Nasdaq audit committee rule after board resignation
Notified Nasdaq on June 18, 2025 of non-compliance with Listing Rule 5605(c)(2)(A) due to Alan Edrick's resignation.
Director Alan Edrick resigns from Harvard Bioscience board effective June 10, 2025
Alan Edrick resigned from the board of directors, effective June 10, 2025.
Harvard Bioscience appoints John Duke to board; incentive share pool increases 3.9M
John Duke appointed to board effective June 2, 2025; will serve on audit and nominating committees.
Harvard Bioscience Q1 net loss $50.3M includes $48M goodwill impairment; guides Q2 revenue $18-20M
Revenue $21.8M vs $24.5M YoY (-11%); net loss $(50.3)M vs $(4.7)M, including $48.0M goodwill impairment.
Harvard Bioscience director Bertrand Loy not standing for re-election at 2025 annual meeting
Bertrand Loy informed company April 10, 2025, he will not stand for re-election at the 2025 Annual Meeting.
Harvard Bioscience receives Nasdaq bid-price deficiency; CFO Cote resigns effective May 12
Nasdaq notified HBIO on April 4, 2025 of non-compliance with $1.00 minimum bid price; 180-day cure through Oct 1, 2025.
Harvard Bioscience enters debt waiver and amendment; substantial doubt about going concern
Fifth Amendment waives default on net leverage ratio covenant as of Dec 31, 2024; covenant testing suspended through March 31, 2025 if milestones met.
Harvard Bioscience Q4 revenue $24.6M, FY 2024 net loss widens to $12.4M
Q4 2024 revenue $24.6M, down 12.8% from $28.2M in Q4 2023.
Harvard Bioscience Q3 revenue falls 13% to $22M; net loss widens to $4.8M
Revenue $22.0M, down 13.4% YoY from $25.4M; gross margin stable at 58.1%.
Harvard Bioscience Q2 revenue $23.1M (-20% YoY); GAAP net loss $2.9M
Q2 revenue $23.1M, down 20% from $28.8M; gross margin 57.2% vs 58.0%.
Alan Edrick elected Class III director with 19,722,574 votes for, 10,861,497 withheld, 4,292,458 broker non-votes.
Harvard Bioscience Q1 revenue falls 18% to $24.5M; posts GAAP net loss of $4.7M
Revenue $24.5M, down 18% YoY from $30.0M; gross margin 60.3% vs 61.2%.
Received $3.1M cash in Q1 2024 from employee retention credits (ERC); expects additional $3.1M in FY2024.
Harvard Bioscience approves 2024 cash incentive plan for CEO and CFO
Compensation Committee approved 2024 annual cash incentive plan on March 21, 2024.
Harvard Bioscience Q4 2023 revenue $28.2M, guides 2024 flat-to-modest growth, margin improvement
Q4 revenue $28.2M, down 1% YoY; gross margin 58.0%, up 230 bps YoY.
Harvard Bioscience prelim FY2023 revenue ~$112.3M; includes $5.1M discontinued product headwind
Preliminary unaudited FY2023 revenue estimate of ~$112.3M, down from $113.3M in FY2022, with $5.1M net headwind from discontinued products.
Harvard Bioscience Q3 revenue $25.4M (-6% YoY); adjusted EBITDA margin 8.9%
Q3 2023 revenues $25.4M vs $26.9M prior year; gross margin improved to 58.1% from 45.2%.
Harvard Bioscience Q2 revenue $28.8M; adj. op. income up to $3.6M; guides FY23 $116-120M
Q2 revenue $28.8M (-1% YoY) as discontinued product headwinds ($1.6M) offset new product growth.
Harvard Bioscience appoints Jennifer Cote as permanent CFO; $300k base salary, 50% bonus target
Jennifer Cote, previously interim CFO since January 2023, appointed permanently as CFO and Treasurer effective June 19, 2023.
Katherine A. Eade and Thomas W. Loewald re-elected as Class II directors with over 24.5M and 25.5M votes for, respectively.
Harvard Bioscience Q1 revenue $30M (+4% YoY); net income $0.6M vs $6.9M loss; adj EBITDA margin 16%
Q1 revenues $30.0M, up 4% from $28.8M in Q1'22; gross margin improved to 61% from 56%.
Harvard Bioscience reports de minimis SVB exposure, no material impact expected
Cash held in Silicon Valley Bank accounts is de minimis; expects full access and no material impact on financial condition or operations.
Harvard Bioscience approves 2023 cash incentive plan for CEO and Interim CFO
Compensation Committee approved 2023 annual cash incentive plan on March 6, 2023.
HBIO Q4 revenue $28.4M (-14% YoY), GAAP net loss $1.7M; guides low-single-digit growth in FY23
Revenues $28.4M, down 14% YoY; negative currency impact of $1.0M.
CFO Michael Rossi resigns from Harvard Bioscience; separation agreement signed
Rossi resigned as CFO and Treasurer effective Dec 31, 2022; remains employee through May 10, 2023 for transition.
Harvard Bioscience sets compensation for Interim CFO Cote: $270K salary, bonus, $75K RSU
Annual base salary of $270,000 as Interim CFO and Treasurer, effective January 1, 2023.
Harvard Bioscience CFO Michael Rossi resigns; Jennifer Cote named interim CFO
Michael Rossi resigns as CFO and Treasurer effective Dec 31, 2022; will provide transition assistance through May 10, 2023.
Harvard Bioscience Q3 revenue down 9% to $26.9M; GAAP operating loss $3.8M vs income $0.5M
GAAP diluted EPS ($0.08) vs ($0.00); adjusted diluted EPS ($0.01) vs $0.06.
Harvard Bioscience Q2 revenue flat, cuts workforce; guides to 1-5% growth and 13-14% op margin
Q2 revenue flat at $29.2M; GAAP operating income $4.0M includes $4.9M litigation benefit.
On June 10, 2025, Alan Edrick resigned from the board of directors of Harvard Bioscience, Inc. (the “Company”), effective June 10, 2025.
On June 2, 2025, the Board appointed John D. Duke to serve as a member of the Board, June 2, 2025.
On May 30, 2025, Thomas Loewald informed the Company of his resignation from the board of directors (the “Board”) of Harvard Bioscience, Inc. (the “Company”), effective May 30, 2025.
One June 2, 2025, the Board appointed Katherine Eade as the Board’s Lead Independent Director.
On April 10, 2025, Bertrand Loy informed the Company that he will not stand for re-election at the Company’s 2025 Annual Meeting.
On April 10 2025, the Board of Directors of the Company appointed Mark Frost to serve as Interim Chief Financial Officer and Treasurer effective upon Ms. Cote’s resignation (the “Effective Date”).
On April 7, 2025, Jennifer Cote notified the Company of her resignation as Chief Financial Officer and Treasurer.
On June 20, 2023, Harvard Bioscience, Inc. (the “Company”) issued a press release announcing the appointment of Jennifer Cote as the Company’s Chief Financial Officer and Treasurer effective as of June 19, 2023.
On December 7, 2022, Michael Rossi notified Harvard Bioscience, Inc. (the “Company”) of his resignation as the Company’s Chief Financial Officer and Treasurer effective December 31, 2022.
On December 8, 2022, the Company appointed Jennifer Cote to serve as Interim Chief Financial Officer and Treasurer effective upon Mr. Rossi’s resignation.
On December 7, 2022, Michael Rossi notified Harvard Bioscience, Inc. (the “Company”) of his resignation as Chief Financial Officer and Treasurer, effective December 31, 2022.
On January 24, 2022, Harvard Bioscience, Inc. (the “Company”) accepted the resignation of Ken Olson for personal reasons from his position as Chief Operating Officer of the Company effective January 31, 2022.
Max materiality 0.90 · Median 0.60 · Most common event earnings